首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   193篇
  免费   18篇
儿科学   1篇
妇产科学   4篇
基础医学   11篇
口腔科学   5篇
临床医学   9篇
内科学   85篇
皮肤病学   7篇
神经病学   13篇
特种医学   2篇
外科学   18篇
预防医学   21篇
肿瘤学   35篇
  2021年   6篇
  2020年   2篇
  2019年   5篇
  2018年   2篇
  2017年   2篇
  2016年   4篇
  2015年   5篇
  2014年   5篇
  2013年   6篇
  2012年   10篇
  2011年   11篇
  2010年   3篇
  2009年   5篇
  2008年   11篇
  2007年   15篇
  2006年   16篇
  2005年   17篇
  2004年   18篇
  2003年   15篇
  2002年   17篇
  2001年   5篇
  2000年   8篇
  1999年   1篇
  1998年   3篇
  1997年   4篇
  1996年   4篇
  1994年   2篇
  1991年   4篇
  1990年   2篇
  1989年   3篇
排序方式: 共有211条查询结果,搜索用时 15 毫秒
1.
2.
In order to assess whether the exclusion of the province of Madrid from the Spanish areas having a high risk of cancer mortality from most locations (1975-1978)--as opposed to what has been observed in other provinces with similar characteristics--has remained in subsequent years, mortality due to malignant tumors in Madrid in 1980-1984 has been studied. Standardized Mortality Ratios (SMR) yielded values less than 100, which were statistically significant for most locations. The magnitude of the SMR observed under the heading "malignant tumor of unspecified location" must be noted, both in men (206,34) and women (189,61). The evolution of this heading as a percentage of total cancer deaths shows that Madrid has values considerably over the national mean, also in men (11,87%) and women (14,83%). The aspects related to the filling of death certificates that could explain a possible distortion of the pattern of cancer mortality in Madrid are discussed.  相似文献   
3.
BACKGROUND: The aim of this paper is to analyse breast cancer mortality in Andalucia (Spain) between 1975 and 1999 based on age-period-cohort. PATIENTS AND METHODS: Mortality data were obtained from the Mortality Registry of Andalucia. Deaths and population were divided into 13 age groups and five 5-year periods. From this, age-specific mortality rates for 17 birth cohorts were computed. These were plotted and fitted to Poisson regression models to assess age, period and cohort effects. RESULTS: The best fit was found for the complete model, which simultaneously considered the effects of age-period-cohort. Cohort effects were found to be more important than period effects in terms of model fit. CONCLUSION: These effects were manifest as a seemingly consistent increase in the relative risk of breast cancer mortality with a three-fold increase in women born in the 1950s relative to those born in the 1890s.  相似文献   
4.
5.
6.
7.
Patients with T-cell acute lymphoblastic leukemias (T-ALLs) within the Leucemies Aigues Lymphoblastiques de l'Adulte-94 (LALA-94) prospective trial were treated with a 4-drug per 4-week induction, with intermediate-dose cytarabine and mitoxantrone salvage treatment for patients not achieving complete remission (CR) in 1 course. Only the latter received allografts, if possible, thus providing an informative setting for assessing early response. Representative patients with T-ALL (91 patients) were classified into surface T-cell receptor (TCR)-expressing T-ALL patients (TCRalphabeta+ or TCRgammadelta+), pre-alphabeta T-ALL patients (cTCRbeta+, TCR-), and immature (IM) cTCRbeta-, TCR- T-ALL patients; 81 patients underwent genotyping for SIL-TAL1, CALM-AF10, HOX11, and HOX11L2. Overall, CR was obtained in 81 (89%) patients; relapse rate was 62% at 4 years and overall survival (OS) rate was 38%. CR rate was significantly lower in IM T-ALL patients after 1 course (45% vs 87%; P < .001) and after salvage (74% vs 97%; P = .002), with the latter inducing a higher rate of CR (9 [64%] of 14) than initial induction. Once CR was obtained, cumulative relapse rates were similar for IM, pre-alphabeta, and TCR+ T-ALL patients (P = .51), but were higher in HOX11L2 (83%) and SIL-TAL1 (82%) T-ALL patients compared with other genetic subgroups (48%; P = .05). This was associated with an inferior OS for HOX11L2 T-ALLs (13% vs 47% in HOX11L2-T-ALLs; P = .009). The majority of patients with HOX11 T-ALL underwent allografting, predominantly in second CR, but were not associated with a superior OS. Both TCR and genotypic stratification can therefore contribute to risk-adapted management of adult T-ALLs.  相似文献   
8.
Julien Rohmer  Amélie Couteau-Chardon  Julie Trichereau  Kewin Panel  Cyrielle Gesquiere  Raouf Ben Abdelali  Audrey Bidet  Jean-Sébastien Bladé  Jean-Michel Cayuela  Pascale Cony-Makhoul  Vincent Cottin  Eric Delabesse  Mikaël Ebbo  Olivier Fain  Pascale Flandrin  Lionel Galicier  Catherine Godon  Nathalie Grardel  Aurélien Guffroy  Mohamed Hamidou  Mathilde Hunault  Etienne Lengline  Faustine Lhomme  Ludovic Lhermitte  Irène Machelart  Laurent Mauvieux  Catherine Mohr  Marie-Joelle Mozicconacci  Dina Naguib  Franck E. Nicolini  Jerome Rey  Philippe Rousselot  Suzanne Tavitian  Louis Terriou  Guillaume Lefèvre  Claude Preudhomme  Jean-Emmanuel Kahn  Matthieu Groh  CEREO  GBMHM collaborators 《American journal of hematology》2020,95(11):1314-1323
FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia (F/P+ MN-eo) is a rare disease: robust epidemiological data are lacking and reported issues are scarce, of low sample-size and limited follow-up. Imatinib mesylate (IM) is highly efficient but no predictive factor of relapse after discontinuation has yet been identified. One hundred and fifty-one patients with F/P+ MN-eo (143 males; mean age at diagnosis 49 years; mean annual incidence: 0.18 case per million population) were included in this retrospective nationwide study involving all French laboratories who perform the search of F/P fusion gene (study period: 2003-2019). The main organs involved included the spleen (44%), skin (32%), lungs (30%), heart (19%) and central nervous system (9%). Serum vitamin B12 and tryptase levels were elevated in 74/79 (94%) and 45/57 (79%) patients, respectively, and none of the 31 patients initially treated with corticosteroids achieved complete hematologic remission. All 148 (98%) IM-treated patients achieved complete hematologic and molecular (when tested, n = 84) responses. Forty-six patients eventually discontinued IM, among whom 20 (57%) relapsed. In multivariate analysis, time to IM initiation (continuous HR: 1,01 [0.99-1,03]; P = .05) and duration of IM treatment (continuous HR: 0,97 [0,95-0,99]; P = .004) were independent factors of relapse after discontinuation of IM. After a mean follow-up of 80 (56) months, the 1, 5- and 10-year overall survival rates in IM-treated patients were 99%, 95% and 84% respectively. In F/P+ MN-eo, prompt initiation of IM and longer treatment durations may prevent relapses after discontinuation of IM.  相似文献   
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号